Enzo Biochem, Inc. (NYSE:ENZ) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

Directors

On January 5, 2017 Dr. Bruce A. Hanna, Ph.D. was elected to the
Board of Directors of Enzo Biochem, Inc. (the Company) as
a Class II Director. Dr. Hanna replaces Dr. Bernard L. Kasten
M.D. whose third and final term as Director expired on January 5,
2017.

Dr. Hanna is currently a Clinical Professor of Pathology and
Clinical Professor of Microbiology at the New York University
School of Medicine, and Adjunct Professor of Basic Science at New
York University College of Dentistry, Adjunct Professor of
Biology, Long Island University. From 2006 to 2015, he served on
the ASM International Committee and WHO Global Committee, from
2000-2012 he served as an Editor of Clinical Microbiology
Reviews, and 1982-2008 was Director of Clinical Microbiology,
Immunology, and 2008-2010 was Interim Director of Pathology,
Bellevue Hospital Center. Dr. Hanna, Ph.D. earned a Bachelor of
Science in Biology from Saint Bonaventure University, a Masters
in Science in Microbiology from Northeastern University, and a
Ph.D. in Microbiology from Saint Johns University. Dr. Hannas
post-doctorate work in Clinical Microbiology was at Mt. Sinai
Hospital.

Amendment to Employment Agreement

On January 5, 2017 the Company entered into amendments to the
Amended and Restated Employment Agreement dated December 4, 2008
between the Company and Elazar Rabbani and the Amended and
Restated Employment Agreement dated December 4, 2008 between the
Company and Barry Weiner to solely increase the amounts of the
base salaries included therein.

Item 5.07 Submission of Matters to a Vote of Security
Holders.

The Company held its Annual Meeting of Shareholders (the
Annual Meeting) on January 5, 2017. The following matters,
all of which were set forth in the Proxy Statement, were voted on
at the Annual Meeting. The final results of such voting are as
indicated below.

1. Election of the nominees listed below to serve as Class II
Directors on the Board of Directors of the Company, to hold
office for a term of three (3) years or until their successors
have been duly elected and qualified:

2. Approve, in a nonbinding advisory vote, the compensation of
the Companys named executive officers:

3. Ratification of the Companys appointment of EisnerAmper LLP as
the Companys independent registered public accounting firm for
the Companys fiscal year ending July 31, 2017:

There were no broker non-votes for this item.

On the basis of the above votes, (i) the nominees listed above
were elected to serve as Class II Directors on the Board of
Directors of the Company, to hold office for a term of three (3)
years or until their successors have been duly elected and
qualified; (ii) the proposal to approve, in a nonbinding advisory
vote, the compensation of the Companys named executive officers
was approved; and (iii) the proposal to ratify the Companys
appointment of EisnerAmper LLP to serve as the Companys
independent registered public accounting firm for the Companys
fiscal year ending July 31, 2017 was approved.

(d) Exhibits.

About Enzo Biochem, Inc. (NYSE:ENZ)

Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women’s health infectious agents, as well as for use in the identification of pathogens for other markets.

Enzo Biochem, Inc. (NYSE:ENZ) Recent Trading Information

Enzo Biochem, Inc. (NYSE:ENZ) closed its last trading session up +0.14 at 7.19 with 137,632 shares trading hands.